← Leaderboards
Francine M Foss
Tufts Medical Center
$122,062
Attributed
$122,062
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$122,062 · 6
By mechanism
R01$79,323 · 1
M01$42,739 · 5
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationHuman SubjectDrug Screening /EvaluationClinical Trial Phase INeoplasm /Cancer ChemotherapyNeoplasm /Cancer ImmunotherapyDosageCombination ChemotherapyMycosis Fungoides LymphomaBlood ChemistryDrug Adverse EffectUrinalysisDeoxyguanosineDeoxycoformycinDeoxyadenosinesMonoclonal AntibodyNeoplasm /CancerAntitumor AntibodyFemaleInosineHuman T Cell LeukemiaDrug InteractionsCombination Cancer Therapy
Grant awards (14)
Cordycepin + deoxycoformycin in refractory Td-T-positive leukemia$0
M01 · FY2002 · RR
Intravenous BCX34 in refractory T cell &non-T cell malignancies$0
M01 · FY2002 · RR
Docetaxel &trastuzumab in HER2 expressing metastatic breast cancer$0
M01 · FY2002 · RR
IL2 with photopheresis for cutaneous T cell lymphoma$0
M01 · FY2002 · RR
IL2 with photopheresis for cutaneous T cell lymphoma$0
M01 · FY2001 · RR
Cordycepin + deoxycoformycin in refractory Td-T-positive leukemia$0
M01 · FY2001 · RR
Docetaxel &trastuzumab in HER2 expressing metastatic breast cancer$0
M01 · FY2001 · RR
Intravenous BCX34 in refractory T cell &non-T cell malignancies$0
M01 · FY2001 · RR
BIOLOGY AND SIGNAL TRANSDUCTION OF THE IL-7 RECEPTOR PROGRAM$79,323
R01 · FY2000 · CA
94010 PHASE I STUDY OF ORAL BCX 34 IN PATIENTS WITH T CELL MALIGNANCIES$42,739
M01 · FY2000 · RR
IL2 with photopheresis for cutaneous T cell lymphoma$0
M01 · FY2000 · RR
Cordycepin + deoxycoformycin in refractory Td-T-positive leukemia$0
M01 · FY2000 · RR
Intravenous BCX34 in refractory T cell &non-T cell malignancies$0
M01 · FY2000 · RR
Docetaxel &trastuzumab in HER2 expressing metastatic breast cancer$0
M01 · FY2000 · RR